WAT

WAT

USD

Waters Corporation Common Stock

$349.570+4.350 (1.260%)

实时价格

Healthcare
Diagnostics & Research
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$345.220

最高价

$349.590

最低价

$341.510

成交量

0.07M

公司基本面

市值

20.8B

所属行业

Diagnostics & Research

国家/地区

United States

交易统计

平均成交量

0.54M

交易所

NYQ

货币

USD

52周价格范围

最低价 $279.24当前价 $349.570最高价 $423.56

AI分析报告

最后更新: 2025年5月28日
由AI生成数据来源: Yahoo Finance, Bloomberg, SEC

WAT: Waters Corporation Common Stock – Unpacking Recent Trends and Future Signals

Stock Symbol: WAT Generate Date: 2025-05-28 14:39:53

Let's break down what's been happening with Waters Corporation and what the tea leaves might be telling us.

Recent News Buzz: A Positive Current

The general feeling from the latest news around Waters Corporation is pretty upbeat. We've seen a few key announcements that paint a positive picture:

  • Analyst Confidence: Baird, a notable firm, just upped its price target for Waters to $374 from $355. That's a strong vote of confidence, suggesting they see more room for the stock to climb.
  • Innovation in Biologics: Waters announced that its Empower Software now plays nice with multi-angle light scattering detectors. This is a big deal for quality control in biologics, which is a growing and critical area in healthcare. It simplifies regulatory compliance, too, which is always a plus for companies in this space.
  • Executive Visibility: The CEO, Udit Batra, is set to speak at the Jefferies Global Healthcare Conference. This kind of participation often signals a company that's confident and looking to engage with the investment community.

Overall, the news flow is definitely leaning positive, with a high AI confidence score of 7840.7% on the sentiment. Analysts are optimistic, and the company is showing off its technological advancements.

Price Check: A Rollercoaster Ride, Now Stabilizing?

Looking back at the last 30 days, Waters' stock has had quite a journey. It started around the $375 mark in late February, then saw a noticeable dip, especially in early April, hitting lows around $300. That was a pretty sharp drop.

However, since mid-April, the stock has been working its way back up. It's been a bit choppy, but the trend has been generally upward. The most recent close was $358.36.

Now, here's where it gets interesting: Our AI model is predicting some significant upward movement. It forecasts a 1.96% increase today, another 2.74% tomorrow, and a substantial 4.33% jump the day after. If these predictions hold, we're looking at a potential target price of $398.55.

Outlook & Ideas: Leaning Towards Opportunity

Putting the news, the price action, and the AI's predictions together, the situation for Waters Corporation seems to favor potential buyers right now.

  • Why it looks good: The positive news sentiment, especially the analyst upgrade and the focus on innovative biologics solutions, provides a strong fundamental backdrop. The stock has recovered from its April dip, and the AI is forecasting continued, strong upward momentum. The current price of $358.36 is also very close to a technical support level of $358.22, which could indicate a good buying opportunity if it holds.
  • Potential Entry Consideration: Given the current price and the AI's optimistic outlook, considering an entry around the current price of $359.13 to $360.97 could be a strategy. This aligns with the idea that the stock is near a support level and poised for predicted gains.
  • Potential Exit/Stop-Loss Consideration: If you're looking to manage risk, a potential stop-loss could be set around $322.52. This level is well below recent trading and would signal a significant shift in the trend. For taking profits, the AI projects a potential target of $398.55, and a more immediate take-profit level could be around $382.69, which aligns with analyst targets and potential resistance.

Company Context: A Healthcare Backbone

Waters Corporation operates in the Diagnostics & Research sector within Healthcare. They're essentially providing the high-tech tools – like liquid chromatography and mass spectrometry systems – that labs use for everything from drug discovery to environmental testing. With 7,600 employees, they're a significant player. Their work in biologics, as highlighted by the recent news, is particularly relevant given the ongoing advancements in that field. While their revenue growth at 3.9% is a bit lower than some might hope, their Return on Equity (ROE) at 40.8% is quite strong, showing efficient use of shareholder money. However, it's worth noting their debt-to-equity ratio is a bit high at 78.58%.

Important Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Investing in stocks carries inherent risks, and you could lose money. Always conduct your own thorough research and consider consulting with a qualified financial professional before making any investment decisions.

相关新闻

PR Newswire

Waters Corporation to Present at the Jefferies Global Healthcare Conference

Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at...

查看更多
Waters Corporation to Present at the Jefferies Global Healthcare Conference
Analyst Upgrades

Baird Maintains Outperform on Waters, Raises Price Target to $374

Baird analyst Catherine Ramsey maintains Waters with a Outperform and raises the price target from $355 to $374.

查看更多
Baird Maintains Outperform on Waters, Raises Price Target to $374
PR Newswire

Waters Integrates Multi-Angle Light Scattering Detectors with Empower Software for Improved Biologics Quality Control and Simplified Regulatory Compliance

Waters Corporation (NYSE:WAT) today announced that its Empower™ Software now supports biologics data acquisition and quality control (QC) analysis...

查看更多
Waters Integrates Multi-Angle Light Scattering Detectors with Empower Software for Improved Biologics Quality Control and Simplified Regulatory Compliance
PR Newswire

Waters Integrates Multi-Angle Light Scattering Detectors with Empower Software for Improved Biologics Quality Control and Simplified Regulatory Compliance

Waters Corporation (NYSE:WAT) today announced that its Empower™ Software now supports biologics data acquisition and quality control (QC) analysis...

查看更多
Waters Integrates Multi-Angle Light Scattering Detectors with Empower Software for Improved Biologics Quality Control and Simplified Regulatory Compliance

AI预测Beta

AI建议

看涨

更新于: 2025年6月13日 01:30

看跌中性看涨

70.9% 置信度

风险与交易

风险等级3/5
中风险
适合于
保守
交易指南

入场点

$349.29

止盈点

$369.60

止损点

$314.61

关键因素

RSI 75.5表明超买条件
PDI 5.4高于MDI 1.7,且ADX 14.2,表明看涨趋势
当前价格非常接近支撑水平$348.35,表明有强烈的买入机会
交易量是平均值的12.5倍(5,331),表明极强的买入压力
MACD 0.2576高于信号线0.1613,表明看涨交叉

保持更新

设置价格提醒,获取AI分析更新和实时市场新闻。